Peer reviewed journal articles and reviews

  • Weber V, Olzscha H, Längrich T, Hartmann C, Jung M, Hofmann B, Horstkorte R, Bork K (2020):
     Glycation Increases the Risk of Microbial Traversal through an Endothelial Model of the Human Blood-Brain Barrier after Use of Anesthetics.
    J Clin Med. 9(11):3672
  • Kulka LAM, Fangmann PV, Panfilova D, Olzscha H (2020):
     Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease.
    Front Cell Dev Biol. 8:425
  • Weber V, Bork K, Horstkorte R, Olzscha H (2020):
     Analyzing the Permeability of the Blood-Brain Barrier by Microbial Traversal through Microvascular Endothelial Cells.
    J Vis Exp. (156)
  • Olzscha H (2019):
     Posttranslational modifications and proteinopathies: how guardians of the proteome are defeated.
    Biol Chem. 400(7):895-915
  • Olzscha H, Fedorov O, Kessler BM, Knapp S, La Thangue NB (2017):
     CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation.
    Cell Chem Biol. 24(1):9-23
  • New M, Sheikh S, Bekheet M, Olzscha H, Thezenas ML, Care MA, Fotheringham S, Tooze RM, Kessler B, La Thangue NB (2016):
     TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.
    Cancer Res. 76(23):6975-6987
  • Olzscha H, Bekheet ME, Sheikh S, La Thangue NB (2016):
     HDAC Inhibitors.
    Methods Mol Biol. 1436:281-303
  • Picaud S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, Olzscha H, Monteiro O, Martin S, Philpott M, Tumber A, Filippakopoulos P, Yapp C, Wells C, Che KH, Bannister A, Robson S, Kumar U, Parr N, Lee K, Lugo D, Jeffrey P, Taylor S, Vecellio ML, Bountra C, Brennan PE, O'Mahony A, Velichko S, Müller S, Hay D, Daniels DL, Urh M, La Thangue NB, Kouzarides T, Prinjha R, Schwaller J, Knapp S (2015):
     Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
    Cancer Res. 75(23):5106-5119
  • Olzscha H, Sheikh S, La Thangue NB (2015):
     Deacetylation of chromatin and gene expression regulation: a new target for epigenetic therapy.
    Crit Rev Oncog. 20(1-2):1-17
  • New M, Olzscha H, Liu G, Khan O, Stimson L, McGouran J, Kerr D, Coutts A, Kessler B, Middleton M, La Thangue NB (2013):
     A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
    Cell Death Differ. 20(10):1306-16
  • New M, Olzscha H, La Thangue NB (2012):
     HDAC inhibitor-based therapies: can we interpret the code?
    Mol Oncol. 6(6):637-56
  • Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, Tartaglia GG, Vendruscolo M, Hayer-Hartl M, Hartl FU, Vabulas RM (2011):
     Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions.
    Cell. 144(1):67-78


Book chapters

  • Olzscha, H., Bekheet, M.E., Sheikh, S., and La Thangue, N.B. (2016). HDAC Inhibitors. Methods in molecular biology 1436, 281-303.
  • Sheikh, S., Bekheet, M., Olzscha, H., and La Thangue, N.B. (2015). Predicting and Monitoring Responses to Epigenetic Drugs. In Drug Discovery in Cancer Epigenetics, G. Egger, and P. Arimondo, eds. (Waltham: Elsevier), 373-406.


Encyclopaedia articles

  • Olzscha, H., New, M., and La Thangue, N.B. (2013). Personalised Cancer Medicine: Fulfilling the Promise. In Encyclopaedia of Life Sciences, J.W. Sons, ed. (Chichester: John Wiley & Sons), 1-10.



  • Olzscha, H. (2010). Analyse struktureller Determinanten der toxischen Wirkung amyloider Proteine. In Fakultät für Chemie und Pharmazie (Munich: Ludwig-Maximilians-Universität), 1-269.